Enter Note Done
Go to previous page in this tab
Session
  • Presentation | Poster - [In-Person Posters Mon] Drug Development: Human
  • Poster
  • ALN-5288, An Investigational RNA Interference Therapeutic Targeting MAPT In Phase 1 Development For Alzheimer’s Disease [Board No. Monday-0104]
  • Board no. Monday-0104
    Set Timezone

Kevin Sloan1, Matthew Whittaker2, Jeffrey Kurz2, Shelley Patrick2, Jon Farley, Ph.D.1, Rosalind Chuang1, Julia Shirvan1, Joe Dybowski2, Kirk Brown2.
1Alnylam Pharmaceuticals, Cambridge, MA, USA, 2
Types
Main Session